Grifols to Acquire Transfusion Diagnostics Business of Novartis for $1,675M
Grifols (NASDAQ: GRFS), a global healthcare company and leading producer of plasma therapies, and Novartis (NYSE: NVS), today announced that they have signed a definitive agreement whereby Grifols will acquire the transfusion diagnostics unit of Novartis for a total amount of US$1,675 million (€1,240 million).
The transaction is part of Grifols' growth
Posted-In: Earnings News Guidance Asset Sales Management M&A Global